Cellectar Biosciences rolls out new clinical trial data for cancer therapy

Cellectar Biosciences has rolled out new clinical trial data showing patients are responding well to one of its cancer therapies.  The drug development firm, which has roots in UW-Madison, recently announced 12-month follow-up results from Phase 2b of its CLOVER WaM clinical trial.  It’s evaluating the use of its Iopofosine I-131 drug, which targets tumor cells while limiting exposure to heal...